KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Berotralstat and Health-Related Quality of Life in Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials.

Teresa Caballero, Sorena Kiani-Alikhan, Douglas T Johnston, Aolin Wang, Lorena Lopez-Gonzalez, Zheng-Yi Zhou, Fan Yang, Hannah H Kim, Sandra Nestler-Parr, Dianne Tomita, Patrick Gillard, Tamar Kinaciyan

Clin Exp Allergy 56(7) 730-738

PMID42036875
PMCIDPMC13327139
DOI10.1111/cea.70274
发表日期2026-04-27
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:生活质量量表图;FIGURE 2:生活质量量表图;FIGURE 3:生活质量量表图;FIGURE 4:生活质量量表图;FIGURE A1:生活质量量表图。
摘要

摘要

BACKGROUND: In the phase 3 APeX-2 and APeX-J trials, improvements in health-related quality of life (HRQoL) were reported for berotralstat, the only oral, once-daily, long-term prophylaxis for hereditary angioedema (HAE). We conducted a post hoc trial analysis to evaluate the impact of berotralstat on HRQoL versus placebo through 24 weeks, and the long-term effects of treatment up to 96 weeks, using pooled APeX-2 and APeX-J patient data. METHODS: Patients receiving berotralstat 150 mg or placebo using the Angioedema QoL (AE-QoL) questionnaire; total and domain scores were analysed. Changes from baseline through Week 24 were compared using mixed models for repeated measures (MMRM) to estimate least squares mean differences (LSMDs) with 95% confidence intervals (CI) and nominal p-values. After Week 24, in the absence of a placebo comparator, long-term changes from baseline were evaluated using within-subject effect sizes (Cohen's d) through Week 96 in patients receiving berotralstat. Clinical meaningful improvements in AE-QoL total and domain scores were assessed by minimal clinically important difference (6-point reduction in AE-QoL total score) and distributional criterion methods, respectively. The manufacturer of berotralstat (BioCryst Pharmaceuticals) funded this study. RESULTS: Overall, 47 and 45 patients received berotralstat and placebo, respectively. At Week 24, berotralstat showed significantly greater improvement in AE-QoL total (LSMD: -7.4; 95% CI: -14.3, -0.6; p < 0.05), functioning domain (LSMD: -10.9; 95% CI: -19.6, -2.3; p = 0.013) and fears/shame domain (LSMD: -8.7; 95% CI: -17.2, -0.2; p = 0.046) scores compared with placebo. Among patients receiving berotralstat, consistent sustained improvements were observed across all AE-QoL domains up to Week 96. Analyses of meaningful improvement in total score and domains showed an increase over time in the proportion of patients achieving meaningful change. CONCLUSION: Berotralstat significantly improved HRQoL versus placebo through 24 weeks and showed long-term beneficial effects through 96 weeks.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Comparison of AE‐QoL score between berotralstat and placebo at Week 24. AE‐QoL, Angioedema Quality of Life Questionnaire; CI, confidence interval; LS, least squares. *Indicates a p ‐value < 0.05.
非 KM Figure
FIGURE 2FIGURE 2 Change from baseline of AE‐QoL total score up to Week 96. Values represent mean change from baseline at Weeks 24, 48, 72, and 96. Negative values indicate improvement. Abbreviations: AE‐QoL: Angioedema Quality of Life Questionnaire; med: medium.
非 KM Figure
FIGURE 3FIGURE 3 Change from baseline of AE‐QoL domain scores up to Week 96. (A) Functioning score; (B) Fears/Shame score; (C) Nutrition score; (D) Fatigue/Mood score. Values represent mean change from baseline at Weeks 24, 48, 72, and 96. Negative values indicate improvement. Abbreviations: AE‐QoL: Angioedema Quality of Life Questionnaire; med: medium.
非 KM Figure
FIGURE 4FIGURE 4 Improvement in AE‐QoL total score per MCID 1 . AE‐QoL, Angioedema Quality of Life Questionnaire; MCID, Minimal clinically important difference. [1] MCID for AE‐QoL was at least a 6‐point decrease from baseline AE‐QoL total score.
非 KM Figure
FIGURE A1FIGURE A1 Improvement over time in AE‐QoL domain scores per distributional criterion method 1 for the berotralstat cohort. AE‐QoL, Angioedema Quality of Life Questionnaire; SD, standard deviation. [1] Define as having change from baseline that achieves a decrease greater than half of the SD of the baseline value where the SD value was based on the baseline value of the pooled berotralstat 150 mg cohort for each AE‐QoL domain score.
非 KM Figure